londamoicitinib; JAK1-IN-7; AZD4604; JAC34RRR7S

Ainm Cheimiceach:

(2R)-N-(3-{5-fluara-2-[2-fluara-3-(methanesulfonyl)ainilino]pirimidin-4-il}-1H-indol-7-il)-3-meatocsa-2- (4-meitilpiperazin-1-il)própánamide

Cód Smiles:

O=C(NC1=CC=CC2=C1NC=C2C3=NC(NC4=CC=CC(S(=O)(C)=O)=C4F)=NC=C3F)(C@H)(N5CCN(C) )CC5)COC

Cód InChi:

InChI=1S/C28H31F2N7O4S/c1-36-10-12-37(13-11-36)22(16-41-2)27(38)33-21-8-4-6-17-18(14- 31-26(17)21)25-19(29)15-32 -28(35-25)34-20-7-5-9-23(24(20)30)42(3,39)40/h4-9,14-15,22,31H,10-13,16H2 ,1- 3H3,(H,33,38)(H,32,34,35)/t22-/m1/s1

Eochair InChi:

JNUZADQZHYFJGW-JOCHJYFZSA-N

Eochairfhocal:

2241039-81-4 ；CAS: 2241039-81-4； CAS: 2241039-81-4；londamocitinib；JAK1-IN-7；AZD4604；AZD-4604；JAC34RRR7S

Tuaslagthacht: 

Stóráil:Tirim, dorcha agus ag 0 - 4 C go gearrthéarmach (laethanta go seachtainí) nó -20 C go fadtéarmach (mí go blianta).

Cur síos:

Is inhibitor roghnach JAK1 éifeachtach é Londamocitinib (AZD4604).

Sprioc: JAK1